Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) shares shot up 6.3% on Wednesday . The company traded as high as $0.17 and last traded at $0.17, 242,023 shares were traded during trading. A decline of 30% from the average session volume of 346,541 shares. The stock had previously closed at $0.16.
The stock’s 50 day moving average price is $0.22 and its two-hundred day moving average price is $0.30. The firm has a market capitalization of $7.55 million, a PE ratio of -0.54 and a beta of 2.04.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. Analysts anticipate that Eyegate Pharmaceuticals Inc will post -0.13 earnings per share for the current year.
In other news, insider Stephen From sold 127,355 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $0.24, for a total transaction of $30,565.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 166,154 shares of company stock valued at $39,877. Corporate insiders own 47.50% of the company’s stock.
A hedge fund recently bought a new stake in Eyegate Pharmaceuticals stock. Susquehanna International Group LLP bought a new position in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 222,297 shares of the specialty pharmaceutical company’s stock, valued at approximately $53,000. Susquehanna International Group LLP owned about 0.49% of Eyegate Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 39.89% of the stock is currently owned by institutional investors.
About Eyegate Pharmaceuticals (NASDAQ:EYEG)
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Read More: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.